Diphenoxylate-Atropine: Pharmacology and Vet Use

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Diphenoxylate-atropine is a prescription antidiarrheal medication developed for people, sold under brand names such as Lomotil, Lonox, and Lomanate. It combines two drugs in one tablet: diphenoxylate, an opioid agonist that slows intestinal motility, and atropine, an anticholinergic drug added in a subtherapeutic amount to discourage deliberate overdose and recreational misuse. The product is not approved by the FDA for use in dogs, cats, or any other animal, and veterinary toxicologists and animal poison control services treat it as a hazard rather than a therapy. Dogs and cats are substantially more sensitive to opioid drugs than humans, so a dose that relieves diarrhea in an adult person can produce profound sedation, respiratory depression, and pinpoint pupils in a pet. The atropine component adds a second layer of risk, including dry mouth, rapid heart rate, and dilated pupils. This article explains the pharmacology of each component, why the combination exists, how opioid and anticholinergic toxicity present in small animals, and why human antidiarrheals should never be given to a pet without direct veterinary guidance.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

What Diphenoxylate-Atropine Is and Why It Exists

Diphenoxylate is a synthetic opioid. It is structurally related to meperidine (pethidine) and, like other opioids, it acts on mu-opioid receptors in the enteric nervous system and central nervous system. When it binds those receptors in the gut wall, it reduces peristalsis, the coordinated wave of muscular contraction that moves intestinal contents forward. Slower transit allows more water to be reabsorbed from the stool, which is the therapeutic goal in simple diarrhea.

At therapeutic doses in humans, diphenoxylate produces little or no euphoria, which is why it was developed as an antidiarrheal rather than an analgesic. At high doses, however, it behaves like a classic opioid and can cause sedation, respiratory depression, and dependence. That dose-dependent shift from gut-selective to brain-active is the reason atropine is included in the formulation.

Atropine is a competitive antagonist at muscarinic acetylcholine receptors. It is added to diphenoxylate products in a deliberately small amount, roughly one part atropine to twenty-five parts diphenoxylate in the common human tablet. The intent is deterrence. A person who takes a handful of tablets to chase an opioid effect will absorb enough atropine to develop an unpleasant anticholinergic reaction: dry mouth, blurred vision, flushing, rapid heartbeat, and difficulty urinating. The discomfort is meant to make recreational use self-limiting. In a pet, that same atropine load is not a deterrent. It is an additional toxic exposure layered on top of opioid toxicity.

The two drugs therefore create a dual-toxicity profile. Diphenoxylate drives the opioid signs (sedation, respiratory depression, pinpoint pupils, slowed gut). Atropine drives the anticholinergic signs (dry mucous membranes, tachycardia, mydriasis, urinary retention). A poisoned animal can show both sets of signs at once, which makes the clinical picture confusing if the exposure history is unknown.

How Diphenoxylate-Atropine Works

Diphenoxylate: Opioid Agonism in the Gut and Brain

Diphenoxylate binds mu-opioid receptors. In the intestine, mu-receptor activation inhibits acetylcholine release from enteric neurons, which reduces the strength and frequency of peristaltic contractions. The result is prolonged contact between luminal contents and the absorptive surface of the colon, so more fluid is reclaimed and stools become firmer and less frequent.

The same receptor population exists in the brainstem, where mu-opioid agonism suppresses the cough reflex and, at higher occupancy, blunts the drive to breathe. Diphenoxylate crosses into the central nervous system, but at labeled human doses the amount reaching the brain is small enough that sedation is uncommon. When the dose rises, or when an animal's blood-brain barrier is less effective at excluding the drug, central opioid effects emerge.

Species differences in opioid sensitivity are well documented across vertebrates. A study of opioid effects using the formalin test in the Speke's hinged tortoise confirmed that opioid-responsive pathways are conserved well beyond mammals, which underscores that opioid drugs act on receptors that are not unique to humans [1]. The practical consequence for small animal practice is that dogs and cats respond to opioid receptor activation with more pronounced central effects than adult humans at comparable exposures.

A second species-specific factor is the blood-brain barrier itself. P-glycoprotein, encoded by the ABCB1 gene, is an efflux transporter that pumps many drugs, including opioids, out of brain tissue. A canine study using a spontaneous P-glycoprotein knockout model demonstrated the principle directly: dogs lacking functional P-glycoprotein developed central nervous system depression after receiving loperamide, another opioid antidiarrheal, while wild-type dogs showed no CNS depression at the same exposure [2]. This finding established that the canine blood-brain barrier depends heavily on P-glycoprotein to keep opioid antidiarrheals out of the brain, and that animals with reduced transporter function are at far greater risk of central opioid toxicity from drugs in this class [2]. The same transporter biology is relevant to diphenoxylate, which is also a P-glycoprotein substrate.

Atropine: Anticholinergic Deterrent

Atropine blocks muscarinic receptors throughout the body. In the gut, muscarinic blockade reduces secretions and motility, which is why atropine has some independent antidiarrheal activity. In the heart, it removes vagal slowing and produces tachycardia. In the eye, it paralyzes the iris sphincter and ciliary muscle, producing mydriasis (dilated pupil) and loss of accommodation. In the salivary glands and airways, it shuts down secretions, producing the classic dry mouth and dry mucous membranes.

At the small doses present in a legitimate human antidiarrheal regimen, these effects are mild. At the doses reached after an overdose, or after a pet swallows a whole bottle, they become prominent and can be life-threatening when combined with opioid respiratory depression.

Labeled Uses and What the Drug Does Not Cover

Diphenoxylate-atropine is labeled for short-term control of diarrhea in humans. It is an adjunct, meaning it reduces symptoms while the underlying cause is addressed or resolves. It does not treat infection, does not rehydrate a patient, and does not correct the electrolyte losses that accompany significant diarrhea.

The drug does not cover several important categories of gastrointestinal disease. It does not treat inflammatory bowel disease, parasitic infection, dietary intolerance, or infectious colitis. In many of those conditions, slowing intestinal transit is actively harmful because it traps organisms, toxins, or inflammatory mediators in the gut for longer. Veterinary texts consistently caution against antimotility drugs in animals with fever, bloody diarrhea, or suspected infectious enteritis for this reason. Diphenoxylate-atropine has no antibacterial, antiparasitic, or anti-inflammatory activity.

For pets, there is no labeled use at all. The product is not approved for dogs or cats, no manufacturer has established a safe dose for those species, and the combination of opioid and anticholinergic toxicity makes the risk-benefit calculation unfavorable even when diarrhea is severe.

How It Is Given and What Happens After

In humans, diphenoxylate-atropine is taken by mouth as a tablet or liquid, usually four times daily, with dosing reduced once diarrhea is controlled. Because the drug slows gut motility, it is typically stopped as soon as symptoms improve rather than continued on a fixed course.

In pets, administration is almost always accidental. A dog or cat finds a dropped tablet, chews through a blister pack, or is given the drug by an owner who assumes a human antidiarrheal is safe for animals. Once swallowed, diphenoxylate is absorbed from the small intestine and distributed to the gut wall, liver, and central nervous system. The atropine is absorbed in parallel.

Onset of clinical signs after accidental ingestion in pets is typically rapid, often within thirty minutes to a few hours, depending on the amount swallowed and whether food was present in the stomach. Because the two drugs have overlapping but distinct time courses, an animal may first appear sedated and then develop a racing heart and dry gums, or the reverse.

Side Effects and What to Do About Them

Opioid-predominant signs

• Sedation ranging from mild drowsiness to deep unresponsiveness
• Respiratory depression, with slow and shallow breathing
• Pinpoint pupils (miosis), a hallmark of opioid effect
• Reduced gut motility, which can progress to ileus and abdominal distension
• Hypothermia at higher doses
• In severe cases, coma and respiratory arrest

Atropine-predominant signs

• Dry mouth and dry mucous membranes
• Tachycardia (rapid heart rate)
• Mydriasis (dilated pupils) and apparent blindness
• Flushed skin and warm extremities
• Urinary retention
• Agitation or disorientation, particularly in cats

What to do

If a pet has swallowed diphenoxylate-atropine, or if the ingestion is suspected, contact a veterinarian or an animal poison control service immediately. Do not wait for signs to appear. Do not attempt to induce vomiting unless a veterinarian instructs you to do so, because sedation and altered swallowing reflexes make aspiration a serious risk. Bring the medication packaging so the veterinarian can identify the product and estimate the dose.

In a clinical setting, management is supportive and directed at the two toxicities. Opioid effects may be reversed with naloxone, an opioid antagonist, though repeated doses or a continuous infusion may be needed because naloxone is shorter-acting than diphenoxylate. Atropine effects are managed with supportive care, including intravenous fluids, monitoring of heart rate and rhythm, and treatment of urinary retention if it develops. Respiratory support, including oxygen and, in severe cases, mechanical ventilation, may be required. Activated charcoal may be considered early after ingestion if the airway is protected.

Which Animals Should Not Receive It

No animal should receive diphenoxylate-atropine without direct veterinary supervision, and in practice there is no established veterinary indication for the product. Certain animals carry additional risk:

• Dogs and cats of any age, because of species-level opioid sensitivity
• Animals with pre-existing respiratory disease, because opioid-induced respiratory depression compounds existing compromise
• Animals with cardiac disease, because atropine-induced tachycardia can destabilize them
• Animals with hepatic or renal disease, because drug clearance is impaired
• Animals with glaucoma, because atropine raises intraocular pressure
• Animals with urinary obstruction or prostatic disease, because atropine can precipitate retention
• Animals already receiving other opioids, sedatives, or anticholinergics, because effects are additive
• Collies and other breeds with ABCB1 (MDR1) mutations, because reduced P-glycoprotein function increases brain exposure to opioid substrates [2]

The ABCB1 point deserves emphasis. The canine knockout model study showed that P-glycoprotein is a major determinant of whether an opioid antidiarrheal reaches the brain [2]. Dogs with the ABCB1-1Delta mutation have a defective transporter and are at markedly higher risk of central opioid toxicity from drugs in this class. This is the same genetic defect that makes ivermectin and several other drugs dangerous in those breeds.

Species Cautions and Clinical Signs

The table reflects a general principle rather than a fixed dose threshold. Any ingestion in a dog or cat should be treated as potentially serious.

Mechanism Overview

The following flowchart traces what happens after a pet swallows diphenoxylate-atropine, from ingestion through the two parallel toxicity pathways.

flowchart TD
    A[Pet swallows tablets] --> B[Gut absorption]
    B --> C[Diphenoxylate enters blood]
    B --> D[Atropine enters blood]
    C --> E[Mu opioid receptor activation]
    E --> F[Slowed gut motility]
    E --> G[Brain opioid effects]
    G --> H[Sedation and slow breathing]
    G --> I[Pinpoint pupils]
    D --> J[Muscarinic receptor blockade]
    J --> K[Dry mouth and tachycardia]
    J --> L[Dilated pupils]
    H --> M[Veterinary emergency care]
    K --> M
    L --> M

Interactions With Other Drugs

Diphenoxylate-atropine interacts with several drug classes, and the interactions matter most in animals already receiving veterinary treatment.

Opioids and other central nervous system depressants add to the sedation and respiratory depression. This includes other opioid analgesics, benzodiazepines, barbiturates, and some anesthetics. A pet recovering from anesthesia or receiving opioid pain control is at higher risk.

Anticholinergic drugs add to the atropine effects. This includes antihistamines, tricyclic antidepressants, some antiemetics, and other antispasmodics. The combined anticholinergic load can produce ileus, urinary retention, and severe tachycardia.

Drugs that inhibit cytochrome P450 enzymes can slow diphenoxylate metabolism and prolong its effects. Monoamine oxidase inhibitors are a labeled contraindication in humans for this reason, and the same caution applies conceptually to animals.

Drugs that are P-glycoprotein substrates or inhibitors can increase brain exposure to diphenoxylate. The canine knockout model established that P-glycoprotein function determines whether opioid antidiarrheals reach the brain [2]. Any animal with reduced transporter function, whether from genetics or from co-administered inhibitors, faces higher central risk.

How It Compares With Alternatives

For pets with diarrhea, veterinarians generally prefer treatments that address the underlying cause rather than simply slowing the gut. Options include dietary management, probiotics, antiparasitic drugs when a parasite is identified, antibiotics when a bacterial cause is confirmed, and fluid therapy for dehydration.

When an antimotility effect is genuinely indicated, veterinarians may consider other agents, but the same cautions about infectious diarrhea apply. The key comparison is not which antidiarrheal is strongest but which is safest for the species and the specific clinical situation. Diphenoxylate-atropine sits at the unfavorable end of that comparison for pets because it combines opioid and anticholinergic toxicity in a package designed for human physiology.

Loperamide, another over-the-counter opioid antidiarrheal, is sometimes mentioned as an alternative. It carries its own serious risk in dogs. The canine P-glycoprotein study used loperamide specifically to demonstrate that ABCB1-mutant dogs develop CNS depression while wild-type dogs do not [2]. That finding is the basis for the widely repeated warning that loperamide is unsafe in Collies and other ABCB1-affected breeds. Diphenoxylate shares the same transporter dependence, so the same caution applies.

The broader lesson is that human antidiarrheals are not interchangeable with veterinary treatments. The physiology of a dog or cat differs enough from a human that a drug designed and dosed for people can be dangerous at any dose in a pet.

Clinical Relevance, Limitations and Common Mistakes

The clinical relevance of diphenoxylate-atropine in veterinary medicine is almost entirely toxicological. It is not a therapeutic option. It is a poisoning hazard that presents with a mixed opioid and anticholinergic syndrome, and it is common enough that animal poison control services field calls about it regularly.

The most common mistake is assuming that a human medication is safe for a pet at a scaled-down dose. Dose scaling does not account for species differences in receptor sensitivity, metabolic clearance, or blood-brain barrier function. A dog or cat is not a small human.

A second mistake is waiting for signs before seeking help. Opioid respiratory depression can progress quickly, and the window for effective decontamination is short. Early contact with a veterinarian or poison control service is the single most useful action an owner can take.

A third mistake is trying to induce vomiting at home. Sedation and altered airway reflexes make aspiration pneumonia a real risk, and the atropine component can slow gastric emptying in unpredictable ways.

A fourth mistake is confusing the mixed signs. Pinpoint pupils point toward opioid effect, while dilated pupils point toward atropine. Seeing both in the same animal is possible and should not be interpreted as contradictory. It reflects the two-drug formulation.

A fifth mistake is failing to mention other medications the pet is receiving. Additive sedation or additive anticholinergic effects can turn a moderate exposure into a severe one.

Individual cases vary. A veterinarian who knows the animal, the exposure, and the timing is the only reliable guide to management.

Reading the Exposure History Like a Toxicologist

The single most valuable skill in managing a diphenoxylate-atropine exposure is not memorizing antidotes. It is reconstructing the ingestion. Owners rarely arrive with a clean story, and the difference between a trivial exposure and a life-threatening one often hides in details that nobody thought to mention.

Work through the history in a fixed order so you do not skip steps under pressure.

Step 1: Identify the exact product. Diphenoxylate-atropine exists as tablets and as an oral liquid, and the two are not equivalent from a decontamination standpoint. Tablets may sit in the stomach for a long time because the atropine component slows gastric emptying, which extends the window in which a veterinarian might reasonably consider decontamination. Liquid formulations are absorbed faster and leave less opportunity for intervention. Ask for the bottle, not a description. Owners frequently confuse Lomotil with loperamide, with bismuth subsalicylate products, or with prescription antispasmodics, and the management differs for each.

Step 2: Establish the number of units missing. Count what remains and subtract from the dispensed quantity on the label. If the owner cannot find the label, ask when the prescription was filled and how often it is taken. A rough estimate is far better than no estimate, provided you document that it is rough.

Step 3: Establish the timing. Onset after ingestion in pets is typically rapid, often within thirty minutes to a few hours. Timing determines whether decontamination is still plausible, whether observed signs are still evolving, and how long the animal needs to be monitored. An animal that swallowed tablets six hours ago and looks normal is not out of danger, because diphenoxylate can produce delayed central effects as absorption continues.

Step 4: Establish the patient's weight and comorbidities. Weight matters for any dose estimate. Comorbidities matter more. An animal with pre-existing respiratory disease has less reserve against opioid-induced hypoventilation. An animal with cardiac disease tolerates atropine-induced tachycardia poorly. An animal with hepatic or renal disease clears the drug more slowly.

Step 5: Establish concurrent medications. This is the step owners omit most often. A pet receiving opioid analgesia after a recent surgery, a pet on a tricyclic antidepressant, a pet on an antihistamine for allergies, and a pet on any sedative all carry an additive burden. Ask specifically about pain medications, behavior medications, allergy medications, and anything given in the last seventy-two hours.

Step 6: Establish the ABCB1 status if the breed raises the question. Collies, Australian Shepherds, Shetland Sheepdogs, Longhaired Whippets, and other breeds with the ABCB1-1Delta mutation have defective P-glycoprotein function. The canine knockout model demonstrated that this transporter is a major determinant of whether an opioid antidiarrheal reaches the brain, with mutant animals developing central nervous system depression while wild-type animals did not at the same exposure [2]. If the breed is consistent with the mutation and the status is unknown, treat the animal as if the transporter is defective. The cost of over-treating a genetically normal dog is far lower than the cost of under-treating a mutant one.

A worked example makes the process concrete. A ten kilogram mixed breed dog is brought in ninety minutes after the owner found an open blister pack of diphenoxylate-atropine tablets on the floor. The owner estimates four to six tablets are missing but is not certain. The dog is drowsy but rousable, with a heart rate of 160 beats per minute, dry gums, and pupils that are difficult to assess because the room is brightly lit.

The history tells you several things at once. The timing is early enough that decontamination may still be worth discussing with the owner, particularly because atropine slows gastric emptying and tablets may remain in the stomach longer than expected. The dry gums and tachycardia point toward anticholinergic effect. The drowsiness points toward opioid effect. The mixed picture is exactly what the two-drug formulation predicts, and it should not be treated as contradictory. The uncertain tablet count means the exposure must be managed as if it were the higher end of the range. The breed is not one typically associated with the ABCB1 mutation, but that does not eliminate risk, because the transporter is only one of several factors determining brain exposure.

Now consider the same dog with a different history. The owner is certain the dog swallowed a single tablet two hours ago, the dog is bright and alert with a normal heart rate and moist gums, and the owner is a veterinary technician who watched the ingestion. The exposure is still not trivial, but the monitoring plan can be proportionate. The point of the structured history is that it lets you scale your response to the actual situation rather than to the word "poisoning."

Step by Step: What Happens in the Clinic

The following sequence reflects how a small animal practice typically approaches a suspected diphenoxylate-atropine ingestion. It is a framework, not a protocol, and it assumes a veterinarian is directing care.

Step 1: Stabilize before you investigate. If the animal is not breathing adequately, that comes first. Opioid-induced respiratory depression is the most immediately life-threatening component of the syndrome. Provide oxygen and support ventilation as needed. Only after the airway and breathing are addressed should you move on to decontamination or diagnostic questions.

Step 2: Place an intravenous catheter. Intravenous access is needed for fluids, for naloxone if it is used, and for any emergency drug. It also gives you a reliable route if the animal deteriorates.

Step 3: Assess perfusion and hydration. Diarrhea, if it preceded the ingestion, may already have caused fluid and electrolyte losses. The opioid component can cause hypothermia at higher doses, and hypothermia complicates everything else. Warm the animal if needed.

Step 4: Perform a focused examination. Record heart rate and rhythm, respiratory rate and effort, mucous membrane moisture, pupil size and responsiveness, mentation, and abdominal palpation. Note whether the bladder is distended, because atropine can precipitate urinary retention. Note whether the abdomen is distended and tympanic, because opioid-induced ileus can progress to that point.

Step 5: Discuss decontamination with the owner. Emesis is generally avoided once sedation is present, because altered swallowing reflexes make aspiration a serious risk. Activated charcoal may be considered early after ingestion if the airway is protected. The decision depends on timing, the animal's mentation, and the veterinarian's judgment. There is no universal rule that applies to every case.

Step 6: Consider naloxone for opioid effects. Naloxone is an opioid antagonist and can reverse the sedation and respiratory depression caused by diphenoxylate. The practical difficulty is duration. Naloxone is shorter-acting than diphenoxylate, so a single dose may wear off while the opioid is still present, and repeated doses or a continuous infusion may be needed. Reversal can also unmask the atropine effects, which were previously masked by sedation. An animal that was quiet and slow may become agitated and tachycardic after naloxone, and that is not a new toxicity. It is the anticholinergic component becoming visible.

Step 7: Manage atropine effects supportively. There is no specific antidote for anticholinergic toxicity in this setting. Intravenous fluids, monitoring of heart rate and rhythm, and treatment of urinary retention if it develops are the mainstays. In cats, agitation and disorientation can be prominent, and a quiet, dimly lit environment helps.

Step 8: Monitor for a sufficient period. The duration of monitoring depends on the amount ingested and the animal's clinical course. Because diphenoxylate can produce delayed central effects and because naloxone may wear off before the opioid does, a period of observation after apparent improvement is prudent. Discharging an animal the moment it looks better is a common and avoidable error.

Step 9: Document and communicate. Record the estimated dose, the timing, the signs observed, the interventions performed, and the response. Give the owner clear written instructions about what to watch for at home and when to return. If the animal was discharged before the full expected duration of effect had passed, say so explicitly.

Troubleshooting the Difficult Case

The animal looks normal but the exposure was large. This is the most deceptive scenario. Opioid effects can be delayed, and the atropine component can mask early sedation by making the animal appear agitated or alert. A normal examination at one hour does not rule out a significant exposure. Err toward longer observation when the history suggests a large ingestion.

The pupils do not match the expected pattern. Pinpoint pupils suggest opioid effect. Dilated pupils suggest atropine effect. Seeing both in the same animal is possible because both drugs are present. If the pupils are dilated and unreactive, do not assume the opioid component is absent. If they are pinpoint, do not assume the atropine component is absent. The pupil finding tells you which drug is currently dominating, not which drugs are on board.

The heart rate is normal. Atropine usually raises heart rate, but a normal rate does not exclude anticholinergic toxicity. The animal may be young and vagally tone-dependent, or the opioid component may be blunting the tachycardia. Treat the whole patient, not the number on the monitor.

The animal deteriorates after naloxone. This is expected in some cases. Naloxone reverses opioid effects and can unmask anticholinergic agitation, tachycardia, and mydriasis. It can also precipitate withdrawal in an animal that has received repeated opioid exposure. The deterioration does not mean the naloxone was wrong. It means the clinical picture has shifted and the monitoring plan needs to shift with it.

The owner wants to induce vomiting at home. Do not endorse this. Sedation and altered airway reflexes make aspiration pneumonia a real risk, and the atropine component can slow gastric emptying in unpredictable ways. If decontamination is appropriate, it should be performed under veterinary supervision with a protected airway.

The owner reports the pet is "just sleepy." Sleepiness in a dog or cat after a suspected opioid ingestion is not a benign finding. It may be the first sign of respiratory depression. Ask about respiratory rate and effort, and if the owner cannot assess those reliably, bring the animal in.

The animal has a history of diarrhea and the owner wants to continue the medication. This is a common and dangerous misunderstanding. The drug is not approved for dogs or cats, and continued administration prolongs both toxicities. The correct response is to stop the medication and address the diarrhea with a species-appropriate plan.

Common Misconceptions, Corrected

Misconception: A smaller dose is safe because the pet is smaller. Dose scaling assumes that the same drug produces the same effect per unit of body weight across species. That assumption fails here. Dogs and cats show more pronounced central opioid effects than adult humans at comparable exposures, and animals with reduced P-glycoprotein function are at even greater risk [2]. A scaled-down human dose is not a safe veterinary dose.

Misconception: The atropine is there to treat the diarrhea. Atropine does have some independent antidiarrheal activity through muscarinic blockade, but that is not why it is in the product. It is added in a deliberately small amount to deter deliberate overdose by producing unpleasant anticholinergic effects in someone who takes too many tablets. In a pet, that deterrent becomes an additional toxic exposure.

Misconception: If the pet is not vomiting, the drug was not absorbed. Absorption and vomiting are separate processes. Diphenoxylate is absorbed from the small intestine, and the atropine component slows gastric emptying, which can delay absorption rather than prevent it. An animal that never vomits can still absorb a significant dose.

Misconception: Loperamide is the safe alternative. Loperamide carries its own serious risk in dogs. The canine P-glycoprotein study used loperamide specifically to demonstrate that ABCB1-mutant dogs develop central nervous system depression while wild-type dogs do not at the same exposure [2]. Diphenoxylate shares the same transporter dependence, so the same caution applies. Neither drug is a safe default for a pet with diarrhea.

Misconception: Antimotility drugs are harmless because diarrhea is not dangerous. Diarrhea itself is usually self-limiting, but the conditions that cause it are not always benign. Slowing intestinal transit can trap infectious organisms, toxins, or inflammatory material in the gut for longer. This is why veterinary texts consistently caution against antimotility drugs in animals with fever, bloody diarrhea, or suspected infectious enteritis.

Misconception: The drug is safe because it is prescription-only. Prescription status reflects regulatory control, not safety in every species. Diphenoxylate-atropine is prescription-only in humans because of its opioid content, and that same opioid content is what makes it dangerous in pets.

Misconception: Opioid receptors work the same way in all animals. Opioid-responsive pathways are conserved well beyond mammals. A study using the formalin test in the Speke's hinged tortoise confirmed that opioid effects can be demonstrated in reptiles, which underscores that these receptors are not unique to humans [1]. Conservation of the receptor, however, does not mean conservation of the response. Species differ in receptor density, drug clearance, and blood-brain barrier function, and those differences determine the clinical outcome.

Misconception: If the pet survives the first few hours, it is out of danger. Diphenoxylate can produce delayed central effects, and naloxone may wear off before the opioid does. A period of observation after apparent improvement is prudent. The absence of signs at one hour is not a discharge criterion.

Practical Applications in Practice

Client education at the pharmacy counter. The most effective intervention is preventing the ingestion in the first place. When a client mentions that they keep diphenoxylate-atropine at home, that is an opportunity to explain that it is not safe for pets and that it should be stored out of reach. This conversation takes thirty seconds and prevents a disproportionate number of emergency visits.

Triage calls. When a client calls to report a suspected ingestion, the person answering the phone sets the tone for the entire case. The goal is to gather the six history elements, advise against home induction of vomiting, and get the animal seen. Do not attempt to reassure the owner that the exposure is probably minor. That judgment belongs to the veterinarian after examination.

Differentiating from other toxicities. A dog presenting with sedation, slow breathing, and pinpoint pupils could have ingested diphenoxylate-atropine, another opioid, or a sedative. A dog presenting with dry gums, tachycardia, and dilated pupils could have ingested an anticholinergic. The combination of both sets of signs in one animal is a strong clue that a mixed opioid-anticholinergic product is involved. Ask specifically about human antidiarrheals when the history is unclear.

Recognizing the ABCB1 patient. Any dog of a breed associated with the ABCB1-1Delta mutation deserves heightened caution with opioid antidiarrheals. The canine knockout model established the mechanism directly [2]. If the status is unknown, treat the animal as if the transporter is defective. This is the same principle that governs ivermectin use in those breeds, and it is worth reinforcing with clients who own affected dogs.

Avoiding the antimotility trap. When a pet presents with diarrhea, the temptation to reach for an antimotility drug is understandable. The safer approach is to identify the cause. Dietary management, probiotics, antiparasitic drugs when a parasite is identified, antibiotics when a bacterial cause is confirmed, and fluid therapy for dehydration are the tools that address the problem rather than masking it. Antimotility drugs have a narrow role even in human medicine, and in veterinary medicine the role is narrower still.

Managing the owner who has already given the drug. Some owners arrive having already administered diphenoxylate-atropine to their pet. The conversation should be direct but not punitive. The priority is to stop further dosing, assess the animal, and explain why the medication is not appropriate. Shame makes owners withhold information, and withheld information makes the case harder to manage.

Documenting for the record. A suspected toxicity case generates a medical record that may be reviewed later. Record the estimated dose, the timing, the signs observed, the interventions performed, and the response. Note explicitly when the estimate is uncertain. Note explicitly when the owner declined a recommended intervention. Clear documentation protects the animal, the owner, and the practice.

Comparative Notes Across Species

The table in the main article summarizes the key cautions. The following notes add depth on why the species differences exist.

Dogs. Canine opioid sensitivity is well recognized, and the P-glycoprotein story explains part of it. The canine blood-brain barrier depends heavily on P-glycoprotein to keep opioid antidiarrheals out of the brain, and dogs with defective transporter function develop central nervous system depression at exposures that leave wild-type dogs unaffected [2]. This is why the ABCB1 mutation is such an important consideration in this class of drugs. Dogs also vary widely in size and breed, and a fixed tablet dose designed for a human adult can represent a very different exposure in a five kilogram dog than in a forty kilogram dog.

Cats. Cats are sensitive to opioids and clear many drugs more slowly than dogs. The atropine component can produce agitation and disorientation that is more prominent than in dogs, and mydriasis in a cat can be dramatic. Urinary retention is a particular concern because cats are prone to urethral obstruction, and atropine can precipitate or worsen retention. The combination of opioid sedation and anticholinergic agitation can produce a clinical picture that is difficult to interpret without a good history.

Humans. The labeled species. At therapeutic doses, diphenoxylate produces little or no euphoria, and the atropine effects are mild. At high doses, the drug behaves like a classic opioid, and the atropine load becomes prominent. The deterrence design works because the anticholinergic effects are unpleasant enough to make recreational use self-limiting in people. That design logic does not transfer to pets, because the deterrent is not perceived as a deterrent by an animal.

Other mammals. There is no label for any other mammal, and the general principle is that opioid and anticholinergic sensitivity should be assumed. Opioid-responsive pathways are conserved across vertebrates, as demonstrated in the Speke's hinged tortoise study [1], so the receptor target is present. What varies is the response, the clearance, and the blood-brain barrier. Without species-specific data, the safe assumption is that the drug is hazardous.

The comparative lesson. The reason diphenoxylate-atropine is a veterinary hazard rather than a veterinary therapy is not that the drug is uniquely dangerous. It is that the drug was designed for a species with different receptor sensitivity, different metabolic clearance, and a different blood-brain barrier. Those differences are not small adjustments. They change the risk-benefit calculation entirely.

Putting It Together

Diphenoxylate-atropine is a human antidiarrheal with a dual mechanism and a dual toxicity profile. Diphenoxylate slows intestinal motility through mu-opioid receptor activation, and atropine is added in a small amount to deter deliberate overdose through unpleasant anticholinergic effects. In pets, both components become liabilities. Dogs and cats show more pronounced central opioid effects than adult humans at comparable exposures, and animals with reduced P-glycoprotein function are at even greater risk [2]. The atropine component adds dry mucous membranes, tachycardia, mydriasis, and urinary retention on top of the opioid sedation and respiratory depression.

The clinical relevance in veterinary medicine is almost entirely toxicological. There is no established veterinary indication for the product in any species. Management is supportive, directed at both toxicities, with naloxone available for opioid effects and supportive care for anticholinergic effects. The most useful action an owner can take is early contact with a veterinarian or animal poison control service. The most useful action a clinician can take is a structured exposure history, a proportionate monitoring plan, and clear client education about why human antidiarrheals are not interchangeable with veterinary treatments.

The broader principle extends beyond this one drug. Human medications are designed for human physiology, and the differences between species are not cosmetic. Receptor sensitivity, metabolic clearance, and blood-brain barrier function all vary, and those variations determine whether a drug helps or harms. Diphenoxylate-atropine is a clear example of a product that is appropriate for its labeled species and hazardous outside it. Recognizing that pattern is more valuable than memorizing any single toxicity.

Frequently Asked Questions

Can I give my dog or cat diphenoxylate-atropine for diarrhea?

No. Diphenoxylate-atropine is not approved for dogs or cats, and it can cause opioid and atropine toxicity in both species. Contact a veterinarian for a species-appropriate treatment instead.

Why does diphenoxylate-atropine contain atropine?

Atropine is added in a small amount to deter deliberate overdose. A person taking many tablets develops unpleasant anticholinergic effects, which makes recreational use self-limiting.

What are the signs of diphenoxylate-atropine poisoning in a pet?

Opioid signs include sedation, slow shallow breathing, and pinpoint pupils. Atropine signs include dry mouth, rapid heart rate, and dilated pupils. Both sets can appear together.

Are dogs and cats more sensitive to opioids than people?

Yes. Dogs and cats show more pronounced central opioid effects than adult humans at comparable exposures, and animals with reduced P-glycoprotein function are at even greater risk.

What should I do if my pet swallowed this medication?

Contact a veterinarian or animal poison control service immediately. Do not wait for signs and do not induce vomiting unless a veterinarian tells you to.

Is loperamide a safer alternative for pets?

No. Loperamide carries its own risk in dogs, particularly in breeds with the ABCB1 mutation, which develop central nervous system depression after exposure.

Can diphenoxylate-atropine be used in any animal species?

There is no established veterinary indication for the product in any species. It is a human medication, and its use in animals is a poisoning risk rather than a therapy.

Why is slowing the gut sometimes harmful in pets with diarrhea?

Slowing transit can trap infectious organisms, toxins, or inflammatory material in the intestine for longer. This is why antimotility drugs are avoided in animals with fever or bloody diarrhea.

Related Articles

• Veterinary Pharmacology Question Bank: How to Use It for NAVLE
• Avian Enrofloxacin: Pharmacology, Clinical Use, and Resistance in Poultry
• What Is a 24-Hour Emergency Vet? How to Use One
• Veterinary Pharmacology Calculations for the NAVLE
• When to Use an Online Vet Instead of Going to the Clinic
• Bandaging Materials in Veterinary Practice: A Guide to Selection and Use
• Acetylcholinesterase Inhibitors: Vet Pharmacology
• Potassium-Sparing Diuretics: Vet Pharmacology

Further Reading

• A narrative review of the clinical applications of tiletamine-zolazepam in canine and feline anesthesia
• Beyond fentanyl: The emergence of xylazine in illicit opioids.
• Medetomidine as a Fentanyl Adulterant: Pharmacology, Detection, Clinical Presentation, and Management
• Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework.

Sources

1. Wambugu, S.N., Towett, P.K., Kiama, S.G., Abelson, K.S.P. and Kanui, T.I. (2009). Effects of Opioids in the Formalin Test in the Speke’s Hinged Tortoise (Kinixys spekii). Journal of Veterinary Pharmacology and Therapeutics, 33, 347-351.
2. P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model.